The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.
Lasmiditan may be effective in the acute treatment of headache pain and most bothersome related symptoms in patients experiencing migraine attacks.
Eli Lily announced positive results from a Phase 3 trial of their first-in-class drug lasmiditan for the acute treatment of migraine.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years